Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Shah on Biomarkers in Gastric/GEJ Cancer

November 19th 2019

Manish A. Shah, MD, discusses biomarkers in gastric and gastroesophageal junction cancer.

Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

November 18th 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.

Dr. Kim on Treatment for BRAF-Mutant Colon Cancer

November 16th 2019

Richard Kim, MD, discusses treatment options for BRAF-mutant colon cancer.

Dr. Hidalgo Medina on Neoadjuvant Therapy in Pancreatic Cancer

November 16th 2019

Manuel Hidalgo Medina, MD, PhD, discusses the emergence of neoadjuvant chemotherapy and radiation in pancreatic cancer.

Rising Incidence of Fatty Liver Disease Holds Implications for Trends in HCC

November 13th 2019

Nonalcoholic fatty liver disease, a risk factor linked to the development of hepatocellular carcinoma and increased mortality, is growing in clinical significance.

Dr. Ocean on Efforts to Improve Early Detection in Pancreatic Cancer

November 12th 2019

Allyson Ocean, MD, discusses efforts to improve early detection rates in pancreatic cancer.

Dr. Eng on Unmet Needs in Early-Onset CRC

November 12th 2019

Cathy Eng, MD, FACP, FASCO, discusses unique barriers facing patients with early-onset colorectal cancer.

Varlitinib Misses PFS, ORR Endpoints in Biliary Tract Cancer

November 12th 2019

Varlitinib combined with capecitabine did not improve progression-free survival nor overall response rate compared with capecitabine/placebo as a second-line treatment in patients with biliary tract cancer.

FDA Grants Priority Review to Nivolumab/Ipilimumab in Advanced HCC

November 11th 2019

The FDA has granted a priority review designation to a supplemental biologics license application for the combination of nivolumab and ipilimumab for the treatment of patients with advanced hepatocellular carcinoma who received prior therapy with sorafenib.

Rapid Progress in HCC Leads to Sequencing Challenges

November 10th 2019

Andreas Kaubisch, MD, sheds light on systemic therapies available in liver cancer and some of the practice-changing phase III trials that have read out in the space.

Avelumab Falls Short as Frontline Maintenance for Gastric/GEJ Cancer

November 9th 2019

Avelumab did not improve overall survival as frontline maintenance following induction chemotherapy in patients with unresectable, locally advanced, or metastatic HER2-negative gastric or gastroesophageal junction cancer.

Expert Highlights Progress and Next Steps in Early Pancreatic Cancer

November 6th 2019

Allyson Ocean, MD, discusses pivotal trials in early pancreatic cancer, the need for genetic testing, and other research efforts focused on improving patient outcomes.

Dr. Rajdev on the Difference Between Cancers and Carcinomas in NETs

November 6th 2019

Lakshmi N. Rajdev, MD, an associate professor, Department of Medicine (Oncology), at Albert Einstein College of Medicine, Montefiore Medical Center, discusses the difference between cancers and carcinomas in neuroendocrine tumors (NETs).

Novel Strategies Progress Through mCRC Pipeline

November 6th 2019

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

PEGPH20 Misses OS Endpoint in Metastatic Pancreatic Cancer

November 4th 2019

The investigational agent pegvorhyaluronidase alfa in combination with gemcitabine and nab-paclitaxel did not show an improvement in overall survival compared with gemcitabine and nab-paclitaxel alone in patients with metastatic pancreatic cancer, missing the primary endpoint of the phase III HALO-109-301 trial.

Wnt Pathway Emerges as Attractive Target in CRC

November 4th 2019

Lukas E. Dow, PhD, discusses ongoing research evaluating Wnt as a potential target in colorectal cancer.

Genetic Testing Guides mCRC Treatment

November 4th 2019

Al B. Benson, MD, discusses personalized treatment strategies for patients with metastatic colorectal cancer.

NGS Is Critical Component in Guiding Advanced Gastric/GEJ Cancer Treatment

November 2nd 2019

Manish A. Shah, MD, discusses ongoing research evaluating immunotherapy and other novel treatments in advanced gastric and gastroesophageal junction cancer.

Dr. Kaubisch on Treatment Options for HCC

November 2nd 2019

Andreas Kaubisch, MD, discusses available treatment options for hepatocellular carcinoma.

Dr. Benson on Frontline Treatment Considerations in mCRC

November 1st 2019

Al B. Benson, MD, discusses key considerations in the frontline treatment of patients with metastatic colorectal cancer.